Patents by Inventor Andrew J. Holman

Andrew J. Holman has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • COMPOUNDS, PHARMACEUTICAL COMPOSITIONS AND METHODS OF TREATMENTS OF IMMUNE RELATED DISEASES AND DISORDERS
    Publication number: 20180117148
    Abstract: Provided herein are methods, pharmaceutical compositions and kits with combination therapies including biopharmaceuticals and neuroregulatory medicines for the treatment of immune related diseases and disorders.
    Type: Application
    Filed: October 27, 2017
    Publication date: May 3, 2018
    Inventor: Andrew J. Holman
  • Methods for determining whether to provide an inhibitor of sympathetic nervous system activity to a human being suffering from an autoimmune disease or fibryomyalgia
    Patent number: 7146205
    Abstract: The present invention provides methods for determining whether to provide an inhibitor of sympathetic nervous system activity to a human being suffering from an autoimmune disease and/or fibromyalgia. The methods of this aspect of the invention each include the steps of: (a) measuring the heart rate variability of a human being suffering from an autoimmune disease or fibromyalgia, to yield heart rate variability data; (b) analyzing the heart rate variability data to determine whether there is excessive sympathetic nervous system activity in the heart of the human being; and (c) providing an inhibitor of sympathetic nervous system activity to the human being if there is excessive sympathetic nervous system activity in the heart of the human being.
    Type: Grant
    Filed: May 19, 2003
    Date of Patent: December 5, 2006
    Assignee: CNS-Rheumatology, Inc.
    Inventor: Andrew J. Holman
  • Methods for determining whether to provide an inhibitor of sympathetic nervous system activity to a human being suffering from an autoimmune disease or fibryomyalgia
    Publication number: 20040171954
    Abstract: The present invention provides methods for determining whether to provide an inhibitor of sympathetic nervous system activity to a human being suffering from an autoimmune disease and/or fibromyalgia. The methods of this aspect of the invention each include the steps of: (a) measuring the heart rate variability of a human being suffering from an autoimmune disease or fibromyalgia, to yield heart rate variability data; (b) analyzing the heart rate variability data to determine whether there is excessive sympathetic nervous system activity in the heart of the human being; and (c) providing an inhibitor of sympathetic nervous system activity to the human being if there is excessive sympathetic nervous system activity in the heart of the human being.
    Type: Application
    Filed: May 19, 2003
    Publication date: September 2, 2004
    Applicant: CNS-Rheumatology, Inc.
    Inventor: Andrew J. Holman
  • Use of dopamine D2/D3 receptor agonists to treat fibromyalgia
    Patent number: 6300365
    Abstract: The present invention is directed to methods for the treatment of human patients afflicted with fibromyalgia using a non-ergot dopamine receptor D2/D3 agonist. In particular, patients are treated with a therapeutically effective amount of tetrahydro-benzthiazole or 3(H)-indolone compounds that are dopamine agonists. More specifically, the compounds 2-amino-6-n-propylamino-4,5,6,7-tetrahydrobenzo-thiazole or 4-[2-(dipropylamino)-ethyl]-1,3-dihydro-2H-indol-2-one are administered to fibromyalgia patients to reduce the musculoskeletal pain symptoms associated with fibromyalgia.
    Type: Grant
    Filed: May 7, 2001
    Date of Patent: October 9, 2001
    Inventor: Andrew J. Holman
  • Use of dopamine D2/D3 receptor agonists to treat fibromyalgia
    Patent number: 6277875
    Abstract: The present invention is directed to metho s for the treatment of human patients afflicted with fibromyalgia using a non-ergot dopamine receptor D2/D3 agonist. In particular, patients are treated with a therapeutically effective amount of tetrahydro-benzthiazole or 3(H)-indolone compounds that are dopamine agonists. More specifically, the compounds 2-amino-6-n-propylamino-4,5,6,7-tetrahydrobenzo-thiazole or 4-[2-(dipropylamino)-ethyl]-1,3-dihydro-2H-indol-2-one are administered to fibromyalgia patients to reduce the musculoskeletal pain symptoms associated with fibromyalgia.
    Type: Grant
    Filed: July 17, 2000
    Date of Patent: August 21, 2001
    Inventor: Andrew J. Holman